Clinical Trial Update: Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating melatonin to mitigate neurocognitive deficits in the St. Jude Lifetime Cohort of cancer survivors; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neurocognitive Impairment

Drugs mentioned

• Melatonin (melatonin)

Snippet

Sponsor: St. Jude Children's Research Hospital | Conditions: Cancer Malignancies | Phase 3 | Status: COMPLETED | Results posted: 2018-06-28